-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RB1d9u31H1i5y8sT2S5jzrVQzowYI2V6LO7SHNKKAJpmiTFFnKPEmvfovIHwf/sd Abi/WGqGcJFX5ICfOuZ6gg== 0001096906-06-001235.txt : 20061019 0001096906-06-001235.hdr.sgml : 20061019 20061019095255 ACCESSION NUMBER: 0001096906-06-001235 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20061019 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20061019 DATE AS OF CHANGE: 20061019 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UTAH MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0000706698 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870342734 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12575 FILM NUMBER: 061152194 BUSINESS ADDRESS: STREET 1: 7043 S 300 WEST CITY: MIDVALE STATE: UT ZIP: 84047 BUSINESS PHONE: 8015661200 8-K 1 utahmed8k101906.htm UTAH MEDICAL PRODUCTS, INC. FORM 8-K OCTOBER 19, 2006 Utah Medical Products, Inc. Form 8-K October 19, 2006



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934



Date of Report (date of earliest event reported): October 19, 2006


Commission File No. 0-11178


UTAH MEDICAL PRODUCTS, INC.
(Exact name of Registrant as specified in its charter)


UTAH
87-0342734
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)


7043 South 300 West
Midvale, Utah 84047
Address of principal executive offices


Registrant's telephone number:    (801) 566-1200




 

 
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
 

 
Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the quarter and nine months ended September 30, 2006 and forward-looking statements relating to 2006 and beyond as presented in a press release dated October 19, 2006. The information in this report shall be deemed incorporated by reference into any registration statement heretofore or hereafter filed under the Securities Act of 1933, as amended, except to the extent that such information is superseded by information as of a subsequent date that is included in or incorporated by reference into such registration statement. The information in this report shall not be treated as filed for purposes of the Securities Exchange Act of 1934, as amended.



 
SIGNATURES


 
Pursuant to the requirements of the Securities Exchanges Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


 
UTAH MEDICAL PRODUCTS, INC.
 
REGISTRANT
     
     
Date:     10/19/2006    
By:
    /s/ Kevin L. Cornwell
   
Kevin L. Cornwell
   
CEO

 

 


 
EXHIBIT INDEX

Index
Number
Description

99.1
Financial information for Utah Medical Products, Inc. for the quarter and nine months ended September 30, 2006 and forward-looking statements relating to 2006 and beyond as presented in a press release dated October 19, 2006.
 
 
 
 

EX-99.1 2 utahmed8k101906ex99-1.htm EXHIBIT 99.1 Exhibit 99.1



EXHIBIT 99.1

Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq:UTMD) reports that for the third calendar quarter (3Q) of 2006 compared to 3Q 2005, consolidated sales were the same, gross profits were down 1%, operating profits were up 34%, net income was up 12%, and earnings per share (eps) were up 14%.

In the 3Q 2006, UTMD achieved the following profit margins:
Gross Profit Margin (gross profits/ sales):
56.7%
Operating Profit Margin (operating profits/ sales):
39.1%
Net Profit Margin (profit after taxes/ sales):
28.6%

Comparing 3Q 2006 sales to 3Q 2005 sales in product categories, gynecology/ electrosurgery product sales were up 16%, blood pressure monitoring/ components sales were the same, neonatal product sales were down 2%, and obstetrics product sales were down 8%. Domestic sales in 3Q 2006 were down 3% while international sales were up 12%, compared to the same quarter last year. Although trade shipments from UTMD Ireland were up 9% in EURO terms, they were up 14% in U.S. Dollar terms because of a weaker U.S. Dollar.

UTMD’s gross profit margin in 3Q 2006 was only 56.7% compared to 57.3% in 3Q 2005, primarily because the current quarter’s sales increases were provided by international shipments at lower than average prices offsetting decreases in domestic sales. Even with a lower gross profit margin on the same sales volume, 3Q 2006 operating profits grew dramatically because operating expenses declined to 17.6% of sales compared to 28.2% of sales in 3Q 2005. Litigation expenses, which are part of G&A expenses, were $710,000 lower than in 3Q 2005. The lower litigation expenses were partly offset by $32,700 in additional (noncash) G&A expenses for estimated option expense according to valuations established by the Black-Scholes model, which were not part of 3Q 2005 expenses. In year-to-date 2006 (9M) operating expenses, the impact of expensing options which did not occur in 2005 was $108,400.

Net income was also up substantially because, in addition to the increase in operating profits, the Company benefited from non-operating income of $267,600 during 3Q 2006 compared to $203,000 in 3Q 2005. Virtually all of UTMD’s excess cash is now invested in short term money market instruments, currently yielding about 5.0%. Partially offsetting the higher non-operating income from investments, the Company’s consolidated provision for income taxes in 3Q 2006 was 33.3% of pretax profits compared to only 20.2% in 3Q 2005. In 2005, UTMD benefited from The American Jobs Creation Act of 2004 which allowed a tax deduction on foreign earnings repatriated in 2005.

All primary income statement measures of financial performance for the first nine months (9M) of 2006 increased compared to 2005, according to the following table:
Sales
+   3%
Gross Profits
+   2%
Operating Profits
+ 13%
Earnings before Taxes (EBT)
+ 19%
Net Income
+   8%
Earnings per Share (EPS)
+ 13%

Eps for the most recent 4 calendar quarters were $1.97.



 

According to CEO Kevin Cornwell, “Although sales in 3Q 2006 were lower than our expectations, we are optimistic that sales will increase in 4Q. Based on an excellent overall operating performance during the first nine months of the year, it appears highly likely that UTMD will achieve its goal of $2.00 eps in 2006.”

Financial ratios as of September 30, 2006 which may be of interest to shareholders follow:
1)  Current Ratio = 8.6
2)  Days in Receivables (based on 3Q sales activity) = 47
3)  Average Inventory Turns (based on 3Q CGS) = 3.7
4)  Year-to-Date ROE = 16% (after dividends)

UTMD=s dilution from unexercised option shares added to actual weighted average outstanding shares for purposes of calculating eps was 91,800 in 3Q 2006 compared to 221,600 in 3Q 2005, and 102,000 in 9M 2006 compared to 223,800 in 9M 2005. The actual number of outstanding shares at the end of 3Q 2006 was 3,933,900 which included 3Q employee option exercises of 16,000 shares and 3Q share repurchases of 7,100 shares. The average price paid by the Company to repurchase shares in the open market during 3Q 2006 was $29.93 including commissions. Year-to-date purchases through 9M 2006 have been 58,800 shares at an average per share cost of $30.69. The total number of outstanding unexercised options at September 30, 2006 was 269,100 shares at an average exercise price of $18.53/ share, including shares awarded but not vested. This compares to 682,500 unexercised option shares outstanding at the end of 3Q 2005.

Investors are cautioned that this press release may contain forward looking statements, and that actual events may differ from those projected. Risk factors that could cause results to differ materially from those projected include market acceptance of products, timing of regulatory approval of new products, regulatory intervention in current operations, the Company’s ability to efficiently manufacture, market, and sell its products, among other factors that have been outlined in UTMD=s public disclosure filings with the SEC. The SEC Form 10-Q for 3Q 2006 will be filed with the SEC by November 9.

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures, assembles and markets a broad range of disposable and reusable specialty medical devices designed for better health outcomes for patients and their care-providers. For more information about Utah Medical Products, Inc., visit UTMD=s website at www.utahmed.com.




 
 
Utah Medical Products, Inc.

INCOME STATEMENT, Third Quarter (3 months ended September 30)
(in thousands except earnings per share):

   
3Q 2006
 
3Q 2005
 
Percent Change
 
Net Sales
 
$
7,001
 
$
7,001
   
-
 
Gross Profit
   
3,971
   
4,014
   
(1.1%)
 
Operating Income
   
2,736
   
2,038
   
+34.3%
 
Income Before Tax
   
3,004
   
2,241
   
+34.0%
 
Net Income
   
2,003
   
1,789
   
+12.0%
 
Earnings Per Share
 
$
0.498
 
$
.436
   
+14.3%
 
Shares Outstanding (diluted)
   
4,021
   
4,104
       

INCOME STATEMENT, First Nine Months (9 months ended September 30)
(in thousands except earnings per share):
 
   
9M 2006
 
9M 2005
 
Percent Change
 
Net Sales
 
$
21,398
 
$
20,681
   
+3.5%
 
Gross Profit
   
12,055
   
11,770
   
+2.4%
 
Operating Income
   
7,963
   
7,061
   
+12.8%
 
Income Before Tax
   
9,216
   
7,731
   
+19.2%
 
Net Income
   
6,098
   
5,645
   
+8.0%
 
Earnings Per Share
 
$
1.508
 
$
1.338
   
+12.7%
 
Shares Outstanding (diluted)
   
4,045
   
4,219
       


BALANCE SHEET
(in thousands)
 
(unaudited)
SEP 30, 2006
 
(unaudited)
JUN 30, 2006
 
(audited)
DEC 31, 2005
 
(unaudited)
SEP 30, 2005
 
Assets
                 
Cash & Investments
 
$
19,854
 
$
18,421
 
$
17,453
 
$
13,580
 
Receivables, Net
   
3,815
   
3,879
   
4,418
   
3,467
 
Inventories
   
3,379
   
3,323
   
3,305
   
3,117
 
Other Current Assets
   
613
   
661
   
682
   
923
 
Total Current Assets
   
27,661
   
26,284
   
25,858
   
21,087
 
Property & Equipment, Net
   
8,347
   
8,360
   
8,160
   
8,301
 
Intangible Assets, Net
   
7,458
   
7,470
   
7,624
   
7,637
 
Total Assets
 
$
43,466
 
$
42,114
 
$
41,642
 
$
37,025
 
Liabilities & Shareholders’ Equity
                         
Total Current Liabilities
 
$
3,231
 
$
2,724
 
$
3,175
 
$
3,169
 
Note Payable
   
4,989
   
5,313
   
5,336
   
-
 
Deferred Income Taxes
   
190
   
187
   
274
   
316
 
Stockholders’ Equity
   
35,056
   
33,890
   
32,857
   
33,540
 
Total Liabilities & Shareholders’ Equity
 
$
43,466
 
$
42,114
 
$
41,642
 
$
37,025
 


 
 

-----END PRIVACY-ENHANCED MESSAGE-----